Legacy Medical Consultants

What Legacy Medical Consultants does

Legacy Medical Consultants L.P. is a privately held Fort Worth, Texas-based specialty wound care company founded in 2020 that distributes advanced biologics and autologous systems for chronic wound management. Its portfolio splits into two categories: an amniotic membrane allograft line (Zenith, Impax, Orion, Complete ACA, SurGraft FT, Reeva FT) spanning single-layer through triple-layer+ configurations, and the ActiGraft autologous whole-blood-clot line (ActiGraft Pro for HOPD settings and ActiGraft Plus for wound clinics and medical offices) acquired as exclusive US rights from Israel-based RedDress in August 2025. All products are terminally sterilized, FDA-regulated solely under Section 361 of the PHS Act per 21 CFR Part 1271, carry a 5-year shelf life at ambient temperature, and are supported by peer-reviewed clinical evidence including a multicenter RCT and a meta-analysis reporting pooled healing RR of 2.75 for amniotic products.

The company sells primarily to licensed healthcare providers — hospitals, wound care clinics, outpatient facilities, and federal VA/DoD sites — through a sales-led, direct-distribution model supplemented by an in-house reimbursement support team offering insurance verification and claims assistance. Revenue is generated via quote-based hardware/allograft sales tied to distinct HCPCS Level II codes (Q4253, Q4262, Q4268, Q4276, Q4302, Q4314 for allografts; G0465 for ActiGraft). GTM is concentrated in the United States, with clinical evidence and peer-reviewed publications serving as the primary marketing lever.

The company is led by CEO Jonathan Knutz, operates with 11-50 employees, and has no disclosed institutional funding or public listing. The DOJ has cited the company in charging documents related to Medicare billing amounting to at least $2.6 billion, an unresolved matter that materially affects the risk profile of the business. Active strategic initiatives include the REBOUND randomized controlled trial for Orion in diabetic foot ulcers (enrollment began December 2025), GPO contracting, and advocacy against proposed Medicare Local Coverage Determinations for skin substitutes.

Name

Legacy Medical Consultants

Legal name

Legacy Medical Consultants L.P.

Website

https://legacymedicalconsultants.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

11–50 employees

Short description

Legacy Medical Consultants is a Fort Worth, Texas-based specialty wound care company that distributes amniotic membrane allografts and autologous blood clot systems to hospitals, wound clinics, VA/DoD facilities, and outpatient centers across the United States under FDA Section 361 regulation.

Ownership category

akta.pro rank

Product category

Wound Care Biologics

NAICS

Medical Equipment and Supplies Manufacturing (3391), Surgical Appliance and Supplies Manufacturing (339113)

SIC

Biological Products, (No Disgnostic Substances) (2836), Wholesale-Medical, Dental & Hospital Equipment & Supplies (5047)

akta.pro primary industry

Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts) (HLAHALAE)

Keywords

• Wound care products
• Amniotic allografts
• Biologic skin substitutes
• Chronic wound management
• Autologous blood clot systems

Headquarters

HQ city

Fort Worth

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Operations, Technology or R&D, Marketing or Sales

Revenue model

1. Medical Device and Allograft Product Sales: Legacy Medical generates revenue through the sale of wound care products including ActiGraft autologous blood clot systems and amniotic membrane allografts to healthcare providers across various care settings including hospitals, wound care clinics, and outpatient facilities.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels3 records

Core offering

Legacy Medical Consultants develops, distributes, and sells advanced wound care products for chronic non-healing wounds. The portfolio includes autologous whole blood clot systems (ActiGraft Pro for hospital outpatient facilities and ActiGraft Plus for wound clinics and medical offices) and a line of terminally sterilized amniotic membrane allografts (Zenith, Impax, Orion, SurGraft FT, Reeva FT, Complete ACA) that serve as protective wound coverings and extracellular matrix scaffolds. Products are sold to healthcare providers across hospitals, wound care clinics, VA and DoD facilities, and outpatient centers in the United States.

Product overview

Legacy Medical Consultants offers a portfolio of advanced wound care products consisting of two categories: autologous whole blood clot systems (ActiGraft Pro and ActiGraft Plus) and amniotic allograft membranes (Zenith, Impax, Orion, SurGraft FT, Reeva FT, and Complete ACA). The ActiGraft products are point-of-care autologous systems that use the patient's own blood to create a protective blood clot scaffold for chronic wound healing. The amniotic allograft line ranges from single-layer (Zenith) to dual-layer (Impax, Orion) to full-thickness (SurGraft FT, Reeva FT) to triple-layer+ (Complete ACA), providing protective wound coverings for various wound types and depths. All products are FDA-regulated under Section 361 of the PHS Act, terminally sterilized, and have 5-year shelf lives at ambient temperature storage.

Differentiator

Problem solved

Functional benefit

Brands

• ActiGraft® Pro: Autologous wound care system for Hospital Outpatient Facilities (HOPD) - creates blood clot from patient's whole blood for chronic wound management
• ActiGraft® Plus
• Zenith™
• Impax™
• Orion™
• Complete ACA™
• SurGraft FT™
• Reeva FT™

Products and services

• ActiGraft Pro Autologous wound care system (HCPCS G0465) for Hospital Outpatient Facilities (HOPD) that creates a blood clot from the patient's own whole blood at point of care, serving as a protective covering for chronic non-healing wounds. No centrifuge needed; approximately 5-minute coagulation; blood can be stored at ambient temperature for up to 24 hours before use.
• ActiGraft Plus Autologous wound care system (HCPCS G0465) for Wound Clinics and Medical Offices that creates a blood clot from the patient's own whole blood, serving as a protective covering to optimize the body's healing potential for chronic non-healing wounds.
• Zenith Amniotic Allograft

Quantifiable outcome

• A multicenter RCT demonstrated statistically significant healing outcomes compared to control for diabetic foot ulcers
• +2 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

One partnership is on record.

• RedDresscoreOEM/ Whitelabel/ Licensing Partner · 19 August 2025Legacy Medical Consultants acquired exclusive US rights to market ActiGraft wound care treatments from RedDress, an Israel-based company. The agreement covers exclusive agent status across all care settings including hospitals, physician offices, VA and DoD facilities, and outpatient wound-care centers. The companies will collaborate on payer-coverage expansion, GPO contracting, and investigator-initiated research to further validate ActiGraft's benefits.

Scale indicators3 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• Organogenesis: Public regenerative medicine company (Apligraf, Dermagraft, PuraPly, Novachor) competing across advanced wound care biologics and skin substitutes in the same physician and hospital channels LMC serves.
• MiMedx: Pure-play amniotic membrane allograft company (EpiFix, AmnioFix) and the dominant US competitor in the skin substitute category directly competing with LMC's Zenith, Impax, Orion, SurGraft FT, Reeva FT, and Complete ACA.
• RedDress: Israel-based developer of the ActiGraft autologous blood clot system; LMC is its exclusive US distributor, making RedDress both a strategic partner and a global peer in autologous wound care.

Broad incumbents

• Smith+Nephew: Global wound management incumbent offering advanced wound care, negative pressure wound therapy, and skin substitutes (e.g., GRAFIX, OSIRIX) targeting the same chronic wound indications as Legacy Medical.
• MTF Biologics: Major tissue bank and regenerative medicine organization distributing amniotic, placental, and dermal allografts (e.g., AmnioBand, AlloPatch) in the same wound care channels as Legacy Medical.
• Integra LifeSciences: Large diversified medical device company with a meaningful wound care franchise (Integra Dermal Regeneration Template, PriMatrix, AmnioExcel) overlapping directly with LMC's allograft and skin substitute portfolio.
• AlloSource: Non-profit tissue bank producing a range of allograft skin and wound care products (e.g., AlloSkin, Amniotic Membrane) directly comparable to LMC's portfolio of amniotic allografts.
• Convatec: Global wound care, ostomy, and continence company offering advanced wound dressings, antimicrobial dressings, and skin substitutes (e.g., InnovaMatrix) directly comparable to LMC's allograft range.
• Coloplast: Major wound and skin care company with products across dressings, ostomy, and bioengineered skin substitutes (e.g., gentamicin-collagen sponge, Biatain) competing for the same hospital, clinic, and outpatient wound-care customers.

Emerging players

• Vivex Biologics: Emerging US allograft and amniotic membrane company with overlapping wound care SKUs and a similar commercial focus on physician offices and outpatient wound centers, positioning it as a comparable growth-stage peer.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks7 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/legacy-medical-consulting

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Legacy Medical Consultants